Royalty Report: Drugs, Biotechnology, Delivery – Collection: 5666

License Grant

The Company grants Licensee an exclusive, royalty-bearing, non-assignable (without Licensor’s prior written permission), license to Licensor Technology with the right to sublicense under terms of Article XIII herein below in the Territory.

License Property

1. U.S. Patent Application Serial No. 08/236,504 (filed April 29, 1994) — entitled Stem-Loop Cloning Method and Vector
2. U.S. Patent Application Serial No. 08/877,251 (filed June 17, 1997) — entitled Stem-Loop Cloning Method and Vector Notice of Allowance December 28, 1998
3. U.S. Patent Application Serial No. 09/169,793 (filed October 9, 1998) – entitled Stem-Loop Cloning Method and Vector
4. U.S. Patent Application Serial No. 09/397,782 (filed September 16, 1999) — entitled In Vivo Production of ssDNA Using Reverse Transcriptase with Predefined Reaction Termination via Step-Loop Formation
5. U.S. Patent Application Serial No. 09/397,783 (filed September 16, 1999) — entitled  Enzymatic Synthesis of ssDNA
6. U.S. Patent Application Serial No. 09/411,568 (filed October 4, 1999) – entitled In Vivo Production of ssDNA Containing DNA Enzyme Sequence with Rnase Activity
7. International Application No. PCT/US99/23936 (filed October 12, 1999 — entitled Production of ssDNA In Vivo
8. International Application No. PCT/US99/23933 (filed October 12, 1999) – entitled Enzymatic Synthesis of ssDNA

Field of Use

Field of Use used in this Agreement means the employment of uses and/or methods described in any issued U.S. Patents, Patent Applications, Continuations, Continuations in Part or Divisional of which Licensor is inventor, assignee, or licensee as well as to Licensor Technology and Confidential Information for the purpose of producing Pharmacogenomic Substances.

License Grant

The Company hereby grants to Licensee an exclusive, world-wide, royalty-bearing license under Licensed Subject Matter to manufacture, have manufactured, and/or sell Licensed Products for use within Licensed Field.

License Property

Technology Rights relates to Stem-Loop Cloning Vectors–includes the use of p-ANTI-T vector to produce short, single stranded Deoxyribonucleic Acid (ssDNA) of desired sequence specification and use of ssDNA in anti-sense, triplex formation, and ribozyme production.

Field of Use

Licensed Field shall mean use of compositions and methods using stem-loop vector technology to produce short, single stranded Deoxyribonucleic Acid (ssDNA) of desired sequence specifications for anti-sense, triplex formation, and ribozyme production and delivery applications thereof.

License Grant

The Licensee has the exclusive License to the rights to the NTP testing technology, which measures the level of a brain protein called neural thread protein (NTP), and which is elevated early in Alzheimer's disease, effective in 1997.   University and the Licensor are part of a sponsored research and licensing agreement, under which the Licensee sponsored the research of the principal investigations into the use of neural thread protein, its antibodies or genes for diagnostic or therapeutic purposes. The Licensee also paid the patent costs for the patent applications filed arising out of this research. In return under the agreement, the licensee received an exclusive worldwide license of the patents to sell products and to use processes encompassed by them.

License Property

The Licensor have discovered Neural Thread Protein, and developed antibodies, probes, and other reagents, patents, and information associated with this protein and are interested in the development of new diagnostic strategies for Alzheimer's Disease and other neurodegenerative diseases ('TECHNOLOGY');

The term 'PATENT RIGHT' shall mean (a) (i) the United States Patent Application Serial No. 07/287,207 filed December 20, 1988 entitled 'Method of Detecting Neurological Disease or Dysfunction,' (ii) the United States CIP Patent Application Serial No. 07/451,975 filed on December 20, 1989, (iii) the United States Patent Application Serial Number 08/055,778 filed May 3, 1993 as a file wrapper continuation, and, (iv) the United States Patent Application Serial Number to be assigned, filed June 6, 1995 as a divisional application,

b) (i) the United States Patent Application Serial No. 08/050,559 filed on April 20, 1993 entitled 'Neural Thread Protein Gene Expression and Detection of Alzheimer's Disease, ' (ii) the United States CIP Patent Application Serial No. 08/230,139 filed on April 20, 1994, (iii) the United States CIP Patent Application 08/340,426 filed on November 14, 1994, (iv) the United States Patent Application Serial No. 08/454,557 filed on May 30, 1995 as a divisional application, and (v) the United States Patent Application Serial No. 08/450,673 filed on May 30, 1995 as a divisional application;

Field of Use

The term 'FIELD OF RESEARCH' shall mean research pertaining to the use of any form of neural thread protein, its antibodies, and any cDNAs or genes or genomic fragments coding for neural thread protein, for diagnostic purposes.

License Grant

Library Technology. Licensor hereby grants to Licensee a worldwide, non-exclusive right and license (without any right to grant sublicenses except to Sublicensed Recipients under the terms and under Licensor's rights in the Library Technology, including, without limitation, any Patent Rights Controlled by Licensor Covering the foregoing, (a) to use the OmniBank II Library and Mutant Mice obtained from the Existing OmniBank Library and (b) to make, use and sell Materials derived therefrom. Licensee's right under the foregoing license to sell Materials shall be subject to Cre-Lox Patents.

License Property

Licensor has technology for and expertise in the generation of mouse embryonic stem cell clones containing gene trap mutations that can be used in the production of knockout mice.

Licensor and Licensee are interested in collaborating in the start-up and initial operations of TIGM, including the endowment of TIGM with a library of such mouse embryonic stem cell clones containing gene trap mutations.

'Bioinformatics Software' means the software for the management and analysis of data relating to the OmniBank II Library and the production, genotyping and phenotypic analysis of knockout mice.

The Bioinformatics Software is an online analytical and decision-support system that catalogs the in vivo characterization of all mouse embryonic stem cell clones contained in the OmniBank II Library. Users can assess and search a wide range of phenotypic information at different levels, including raw data, calculated graphs with annotated summaries, and statistical analysis for selected diagnostic areas, by means of a standard web browser. Information can be retrieved through an intuitive search interface by gene description and sequence, disease indication, keywords, related publications and statistical significance.

'Materials' means Mutant Mice, Progeny and cells, tissues and other biological materials derived from any of the foregoing; provided that Materials shall not include cells, tissues or other biological materials that do not contain a Selected Mutation.

'Progeny' means mice, including successive generations thereof, that are produced, developed or derived by or on behalf of TIGM or Sublicensed Recipients directly or indirectly from a Mutant Mouse progenitor.

CRE-LOX PATENTS
4,959,317

GENE TRAPPING PATENTS
USA                                6,136,566     10/24/00      10/4/2016
USA                                6,207,371     3/27/01       10/4/2016
PCT        PCT/US98/16373
USA                                6,139,833     10/31/00      8/8/2017
PCT        PCT/US99/06474
USA                                6,080,576     6/27/00       4/8/2018
PCT        PCT/US99/27366
USA                                6,436,707     8/20/02       4/8/2018
USA                                6,776,988     8/17/04       7/26/2019
USA                                6,218,123     4/17/01       8/10/2019
USA                                6,855,545     2/15/05       2/27/2017
USA                                6,808,921     10/26/04      4/18/2018